pyrazines has been researched along with Recrudescence in 309 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.65) | 18.7374 |
| 1990's | 1 (0.32) | 18.2507 |
| 2000's | 112 (36.25) | 29.6817 |
| 2010's | 180 (58.25) | 24.3611 |
| 2020's | 14 (4.53) | 2.80 |
| Authors | Studies |
|---|---|
| Atallah, E; Chiba, S; Hasabou, N; Hosono, N; Kim, HJ; Larson, RA; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Neubauer, A; Onozawa, M; Perl, AE; Podoltsev, NA; Récher, C; Schiller, GJ; Sierra, J; Strickland, S; Tiu, R; Wang, ES; Yoon, SS | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
| Adachi, S; Akazawa, R; Hiramatsu, H; Kamitori, T; Kato, I; Saida, S; Takeshita, S; Takita, J; Tasaka, K; Uchihara, Y; Umeda, K; Usami, A; Yoshioka, Y | 1 |
| Baer, MR; Bahceci, E; Berman, E; Chou, WC; Ciceri, F; Cortes, JE; Di Stasi, A; Erba, HP; Fabbiano, F; Fathi, AT; Hasabou, N; Hosono, N; Kasner, M; Larson, RA; Lee, JH; Levis, MJ; Liu, C; Liu, X; Martinelli, G; Montesinos, P; Neubauer, A; Olin, R; Paolini, S; Pardee, T; Perl, AE; Podoltsev, N; Recher, C; Stuart, R; Ustun, C; Yokoyama, H; Yoon, SS | 1 |
| Aurran-Schleinitz, T; Chen, DY; Cheson, BD; D'Sa, S; Forconi, F; Frigault, MM; Furman, RR; Greenwald, D; Hamdy, A; Iyengar, S; Izumi, R; Kastritis, E; Kersten, MJ; Kothari, J; Lee, SK; McCarthy, H; Minnema, MC; Mittag, D; Owen, RG; Patel, P; Rule, S; Thomas, SK; Tournilhac, O; Walter, H; Wei, H; Zinzani, PL | 1 |
| Ando, T; Katsuya, H; Kidoguchi, K; Kimura, S; Kojima, K; Kubota, Y; Kusaba, K; Sano, H; Yamaguchi, K; Yokoo, M; Yoshihara, S | 1 |
| Arakawa, Y; Fukuoka, K; Hiraki, T; Inoue, K; Isobe, K; Koh, K; Mitani, Y; Mori, M; Noguchi, J; Oshima, K; Sugawa, M; Takaki, T; Tomita, O; Tsumura, Y; Yanagi, M | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC | 1 |
| Kumar, N; Nayak, SK; Palanisamy, NV; Palanivelu, C; Parthasarathi, R; Sabnis, SC | 1 |
| Ballesta-López, O; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Solana-Altabella, A | 1 |
| Myers, R; Tollkuci, E; Tran, T | 1 |
| Lim, KJC; Tam, CS | 1 |
| Badillo, M; Flowers, C; Jain, P; Kanagal-Shamanna, R; Lee, HJ; Li, S; Nair, R; Nastoupil, L; Navsaria, L; Ok, CY; Patel, KM; Tang, G; Vega, F; Wang, L; Wang, ML; Yin, CC; Zhang, S | 1 |
| Fujita, N; Ito, T; Kasamatsu, Y; Kunimitsu, K; Matsubara, S; Munakata, N; Sasao, A; Tsuboi, H; Tsuchido, Y; Yamawaki, M | 1 |
| Altman, JK; Baer, MR; Bahceci, E; Claxton, D; Cortes, J; Erba, HP; Gill, S; Goldberg, S; Jurcic, JG; Larson, RA; Levis, M; Litzow, M; Liu, C; Martinelli, G; Neubauer, A; Perl, AE; Ritchie, E; Röllig, C; Schiller, G; Smith, C; Spira, AI; Strickland, SA; Stuart, R; Tibes, R; Ustun, C; Wang, ES | 1 |
| Casasnovas, O; Covey, T; Damaj, G; Davies, A; Doorduijn, J; Dua, R; Dupuis, J; Eek, R; Goy, A; Hamdy, A; Huang, X; Izumi, R; Jacobsen, E; Jurczak, W; Kater, AP; Lamy, T; Le Gouill, S; Morschhauser, F; Oberic, L; Panizo, C; Patel, P; Robak, T; Rothbaum, W; Rule, S; Shah, B; Slatter, JG; Smith, SD; Wang, M; Zinzani, PL | 1 |
| Burthem, J; Gorcea, CM; Tholouli, E | 1 |
| Assouline, S; Awan, FT; Hill, B; Patel-Donnelly, D; Rao, AV; Sharman, JP; Thirman, MJ; Ye, W | 1 |
| Appleby, N; Boucher, R; Cabes, M; Eyre, TA; Fox, S; Hillmen, P; Jackson, A; Rawstron, A; Schuh, A; Yates, F | 1 |
| Canaani, J; Carroll, M; McMahon, CM; Morrissette, JJD; Perl, AE; Qualtieri, JN; Rea, B; Sargent, RL; Watt, CD | 1 |
| Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D | 1 |
| Rajkumar, SV | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L | 1 |
| Mahindra, A; Saini, N | 1 |
| Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G | 1 |
| Abdulkadyrov, KM; Bessmel'tsev, SS; Martynkevich, IS; Romanenko, NA; Rugal', VI; Udal'eva, VIu; Zenina, MN | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Pantani, L; Perrone, G; Pezzi, A; Rocchi, S; Tacchetti, P; Tosi, P; Zamagni, E; Zannetti, BA | 1 |
| Colvin, J; Evens, AM; Gordon, LI; Helenowski, I; Kline, J; Larsen, A; Rosen, ST; Smith, SM; van Besien, KM; Winter, JN | 1 |
| Bakhous, A; Waheed, S; Zhu, H | 1 |
| Mark, TM; Meadows, JP | 1 |
| Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L | 1 |
| Baum, C; Deuse, T; Reichenspurner, H | 1 |
| Alinari, L; Baiocchi, RA; Blum, KA; Byrd, JC; Johnston, JS; Li, X; Lin, TS; Lustberg, ME; Porcu, P | 1 |
| Bernard, M; Bosq, J; Camara-Clayette, V; Fest, T; Koscielny, S; Lamy, T; Lazar, V; Lenoir, G; Ribrag, V; Roux, S | 1 |
| Atanackovic, D; Schilling, G | 1 |
| de Jong, H; Schreuder, MF; van Balen, T; van de Kar, NC | 1 |
| Adam, Z; Greil, R; Kasparu, H; Leitgeb, C; Linkesch, W; Ludwig, H; Pour, L; Rauch, E; Seebacher, A; Weißmann, A; Zojer, N | 1 |
| Ma, A; Mazepa, MA; Moll, S; Park, YA; Raval, JS | 1 |
| Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W | 1 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Midorikawa, K; Nagata, A; Noto, S; Ootsubo, K; Sekiguchi, N; Takezako, N; Wagatsuma, M; Yamada, K | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH | 1 |
| Matevosyan, K; Rutherford, C; Sarode, R; Shen, YM; Yates, S | 1 |
| Cavalli, M; Chiarenza, A; Conticello, C; Cunsolo, R; Di Raimondo, C; Di Raimondo, F; Palumbo, GA; Romano, A; Vetro, C | 1 |
| Ashikaga, T; Keino, D; Kinoshita, A; Kondoh, K; Morimoto, M; Ohyama, R; Yamashita, A | 1 |
| Levy, Y; Maisel, C; Robinson, S; Tong, AW | 1 |
| Barchnicka, A; Blajer-Olszewska, B; Blonska, D; Boguradzki, P; Charlinski, G; Dawidowska, D; Dmoszynska, A; Druzd-Sitek, A; Dzierzak-Mietla, M; Gawron, L; Gontarska, A; Grygoruk-Wisniowska, I; Grzasko, N; Holojda, J; Iskierka, E; Jachalska, A; Jurczyszyn, A; Kopacz, A; Lech-Maranda, E; Madro, E; Masternak, A; Nowicki, A; Olszewska-Szopa, M; Potoczek, S; Rybicka, M; Rymko, M; Rzepecki, P; Soroka-Wojtaszko, M; Subocz, E; Swiderska, A; Swistek, W; Torosian, T; Usnarska-Zubkiewicz, L; Walter-Croneck, A; Wisniewska-Piaty, K; Zielinska, P | 1 |
| Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Mahmood, S; Pinney, JH; Rannigan, L; Sachchithanantham, S; Venner, CP; Wechalekar, AD; Whelan, CJ | 1 |
| Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K | 1 |
| Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M | 1 |
| Amaravadi, RK; Bradner, JE; Chang, YC; Davis, LE; Heitjan, DF; Kaplan, J; Mallon, G; Nichols, CW; Paul, TM; Piao, S; Pontiggia, L; Porter, DL; Rangwala, R; Scott, EC; Stadtmauer, EA; Tan, KS; Vogl, DT | 1 |
| Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
| Ba-Mancini, A; Comenzo, RL; Duh, MS; Gravel, J; Knopf, KB; Lafeuille, MH; Lefebvre, P; Ma, E; Niculescu, L; Shi, H | 1 |
| Boccadoro, M; Callea, V; Caltagirone, S; Cangialosi, C; Carovita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Falcone, AP; Ferrero, S; Genuardi, E; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Oliva, S; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Rossini, F; Terragna, C; Urbano, M | 1 |
| Cabanillas, F; Chen, CS; Craig, M; Esseltine, DL; Hanna, WT; Neuwirth, R; O'Connor, OA | 1 |
| Chim, CS; Wong, KY | 1 |
| Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E | 1 |
| Martin, TG | 1 |
| Mateos, MV; Miguel, JF | 1 |
| Boise, LH; Lonial, S | 1 |
| Vij, R | 1 |
| Orlowski, RZ | 2 |
| Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M | 1 |
| Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Kukreti, V; Merlini, G; Palladini, G; Pei, L; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA | 1 |
| Baz, RC; Bose, P; Colevas, AD; Coppola, D; Dawson, J; Doyle, LA; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Honeycutt, C; Kang, L; Kmieciak, M; Peer, CJ; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Sankala, H; Shrader, E; Stuart, RK; Sullivan, D; Tombes, MB; Wan, W; Weir-Wiggins, C; Wellons, M | 1 |
| Hobeika, L; Self, SE; Velez, JC | 1 |
| Bandekar, R; Bladé, J; Cavenagh, JD; Dimopoulos, MA; Gercheva, L; Goranova-Marinova, V; Maiolino, A; Masszi, T; Orlowski, RZ; Puchalski, TA; Reddy, M; Robak, T; Rossi, JF; Samoylova, O; Špička, I; Sutherland, H; Suvorov, A; van de Velde, H; Williams, C; Xie, H | 1 |
| Imai, K | 1 |
| Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K | 1 |
| Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
| Bladé, J; Fernández de Larrea, C; Rosiñol, L | 1 |
| Nakaseko, C; Sakaida, E; Takeda, Y | 1 |
| Augustson, B; Baker, B; Campbell, P; Catalano, J; Copeman, M; Dean, J; Feng, H; Harrison, SJ; Link, E; Prince, HM; Quach, H; Romeril, K; Schwarer, A; Spencer, A; Van De Velde, H | 1 |
| Chiba, S; Hasegawa, Y; Ito, Y; Kurita, N; Miyamoto, K; Obara, N; Ogawa, S; Otsu, K; Sakata, A; Sakata-Yanagimoto, M; Seki, M; Yokoyama, Y | 1 |
| Awan, FT; Barrientos, JC; Brown, JR; Byrd, JC; Chaves, J; Covey, T; Devereux, S; Diacovo, TG; Fardis, M; Furman, RR; Ghia, P; Hamdy, A; Harrington, B; Hillmen, P; Huang, J; Izumi, R; Johnson, AJ; Johnson, D; Jones, JA; Kaptein, A; Lannutti, BJ; McGreivy, J; O'Brien, S; Pagel, JM; Rothbaum, W; Schuh, A; Stephens, DM; Wang, X; Wierda, WG; Woyach, J | 1 |
| Burki, TK | 1 |
| Cavallo, F; Esseltine, D; Fink, L; Guerrero, J; Prasad, HK; Zangari, M | 1 |
| Barton, J; Farley, C; Greco, FA; Hainsworth, JD; Hon, J; Schreeder, M; Spigel, DR | 1 |
| Fujihara, S; Imataki, O; Kirizume, K; Ohnishi, H; Ohue, Y; Shintani, T; Waki, F | 1 |
| Arpaci, F; Ataergin, S; Demiriz, M; Ozet, A | 1 |
| Allen, C; Arun, P; Chen, Z; Nottingham, L; Saigal, K; Van Waes, C | 1 |
| Beveridge, RA; Conner, TM; Doan, QD; LeBlanc, AL; Walters, IB | 1 |
| Anderson, KC; Bladé, J; Boral, AL; Coleman, M; Esseltine, DL; Facon, T; Harousseau, JL; Irwin, D; Niesvizky, R; Rajkumar, SV; Richardson, PG; Rosiñol, L; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Anderson, KC; Ben-Yehuda, D; Chanan-Khan, A; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Anderson, KC; Bladé, J; Cavenagh, J; Esseltine, DL; Harousseau, JL; Jakubowiak, AJ; Lonial, S; Rajkumar, SV; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P | 1 |
| Anagnostopoulos, N; Christoulas, D; Croucher, P; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Heath, D; Kastritis, E; Roussou, M; Terpos, E; Tsionos, K | 1 |
| Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, SA; Niesvizky, R; Richardson, PG; Siegel, DS | 1 |
| Iida, S | 1 |
| Anderson, KC; Crawford, B; Dhawan, R; Gupta, S; Irwin, D; Lee, SJ; Massaro, J; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P | 1 |
| Belch, AR; Corso, A; Komarnicki, M; Lucio, MN; Maiolino, A; Mikhael, JR; Musto, P; Petrucci, MT; Prince, HM; Stewart, AK | 1 |
| Bladé, J; Cibeira, MT; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH | 1 |
| Amato, AA; Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Reece, D; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Wen, PY | 1 |
| Basu, S; Cavenagh, J; Cook, M; Craddock, C; Foot, N; Hallam, S; Harding, S; Joel, S; Oakervee, H; Odeh, L; Popat, R; Singer, C; Williams, C | 1 |
| Abaya, CD; Berenson, JR; Duvivier, H; Mapes, R; Nassir, Y; Patel, R; Swift, RA; Yellin, O | 1 |
| Fujiwara Yamada, M; Harigae, H; Ishikawa, I; Ishizawa, K; Kameoka, J; Ohguchi, H; Okuda, M; Onishi, Y; Sugawara, T; Tomiya, Y; Yamamoto, J | 1 |
| Chen, Q; Hunsucker, SA; Kuhn, DJ; Nemeth, JA; Orlowski, RZ; Small, GW; Voorhees, PM | 1 |
| Butcher, BE; Cannell, P; Horvath, N; Mikhael, JR; Prince, HM; Quach, H | 1 |
| Dispenzieri, A; Gertz, MA; Kumar, S; Sadek, I | 1 |
| Algarotti, A; Corso, A; Lazzarino, M; Mangiacavalli, S; Pascutto, C; Pica, GM; Varettoni, M; Zappasodi, P | 1 |
| Badros, A; Baer, MR; Burger, AM; Egorin, MJ; Espinoza-Delgado, I; Goloubeva, O; Grant, S; Harris, C; Holleran, JL; Kolla, SS; Niesvizky, R; Philip, S; Wright, JJ; Zwiebel, J | 1 |
| Baryshnikov, AIu; Golenkov, AK; Klinushkina, EF; Kogarko, IN; Liubimova, NV; Mitina, TA | 1 |
| Barbarousi, D; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Primenou, E; Roussou, M; Terpos, E; Zagouri, F | 1 |
| Anderson, KC; Boral, A; Facon, T; Harousseau, JL; Irwin, D; Neuwirth, R; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Vogl, DT | 1 |
| Endo, T; Fujimoto, K; Goto, H; Kasahara, I; Koike, T; Nishio, M; Sato, N; Takeda, Y; Yamaguchi, K; Yamamoto, S | 1 |
| Carloss, H; Druck, M; Kerr, R; Lee, M; Lopez, J; Noga, SJ; Sood, R; Walters, IB | 1 |
| San Miguel, JF | 1 |
| Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E | 1 |
| Aulino, J; Baumann, J; Burkey, B; Chung, CH; Cmelak, AJ; Gilbert, J; Hatakeyama, H; Muldowney, NJ; Murphy, BA; Netterville, J; Parker, J; Shyr, Y; Sinard, R; Slebos, RJ; Yarbrough, WG | 1 |
| Bargetzi, M; Heizmann, M; Kotrubczik, N; Moosmann, P; Wernli, M | 1 |
| Bernardeschi, P; Ferreri, MI; Fiorentini, G; Giustarini, G; Montenora, I; Pirrotta, MT; Simi, P | 1 |
| Attal, M; Bourin, P; Laroche, M; Lemaire, O | 1 |
| Bitter, M; Brunvand, MW | 1 |
| Adam, Z; Buchler, T; Hajek, R; Koza, V; Kralova, D; Krejci, M; Krivanova, A; Mayer, J; Pour, L; Sandecka, V; Schutzova, M; Scudla, V; Tothova, E; Vorlicek, J; Zahradova, L | 1 |
| Asmar, L; Barrera, D; Boehm, KA; Boston, J; Boyd, T; Cochran, EW; Di Bella, N; Dien, PY; Kolibaba, K; Lyons, R; Raju, R; Schlegel, PJ; Taetle, R; Vukelja, SJ; Wang, Y | 1 |
| Cherem, L; Kahan, BD; Kaposztas, Z; Katz, SM; Van Buren, CT | 1 |
| Dana, K; Hana, S; Jaroslav, M; Jiri, V; Lucie, K; Ludek, P; Marta, K; Martina, A; Miroslav, P; Roman, H; Tomas, B; Zdenek, A | 1 |
| Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Evens, AM; Gerecitano, J; Gonen, M; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, J; Zelenetz, AD | 1 |
| Dreyling, M; Hartmann, E; Hutter, G; Rosenwald, A; Weinkauf, M; Zimmermann, Y | 1 |
| Dimopoulos, MA; Gillmore, JD; Hawkins, PN; Kastritis, E; Merlini, G; Palladini, G; Perfetti, V; Wechalekar, AD | 1 |
| Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E | 1 |
| Anderson, KC; Badros, A; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Kunsman, J; Leduc, R; Matous, J; Padmanabhan, S; Richardson, PG; Rourke, M; Sam, A; Treon, SP; Warren, D; Weller, E | 1 |
| Richards, T; Weber, D | 1 |
| Hoevenaren, A; Hoevenaren, IA; Levenga, H; Minnema, MC; Raymakers, R; van Vulpen, LF | 1 |
| Acharya, M; Burris, H; Chatta, G; Karol, M; Keith Stewart, A; Lonial, S; Mohrbacher, AF; Neuwirth, R; Reece, DE; Riordan, WJ; Shustik, C; Sullivan, D; Venkatakrishnan, K; von Moltke, LL; Zannikos, P | 1 |
| Dingli, D; Rajkumar, SV | 1 |
| Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Chen, C; Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Treon, SP | 1 |
| Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| Jagannath, S; Mazumder, A; Vesole, DH | 1 |
| Bruna, J; Clapés, V; Navarro, X; Petit, J; Velasco, R; Verdú, E | 1 |
| Dimopoulos, MA; Jagannath, S; Lonial, S | 1 |
| Cook, WJ; Elkins, S; Gaston, RS; Kumar, V; Prendergast, MB; Reddy, V; Sanders, PW | 1 |
| Bladé, J; Buda, G; Cohen, N; Favis, R; Harousseau, JL; Huang, CC; Orlowski, RZ; Ricci, D; Sonneveld, P; Zhuang, SH | 1 |
| Chang, H; Jiang, NN; Qi, X; Reece, D; Trieu, Y; Xu, W | 1 |
| Cho, GJ; Choi, YJ; Chung, JS; Joo, YD; Kim, SG; Kim, SH; Lee, GW; Lee, HS; Lee, SM; Seol, YM; Shin, HJ; Song, MK; Yun, EY | 1 |
| Albitar, M; Anderson, KC; Badros, AZ; Berman, D; Jagannath, S; Messina, M; Richardson, PG; Tarantolo, S; Wolf, JL | 1 |
| Burbury, K; Harrison, SJ; Joyce, T; Peinert, S; Prince, HM; Ritchie, D; Seymour, JF; Stokes, K; Thompson, PA; Wolf, M | 1 |
| Ackerman, E; Berenson, JR; Eades, B; Mapes, R; Swift, RA; Waterman, GN; Yellin, O | 1 |
| Cavalli, F; Conconi, A; Devizzi, L; Ferreri, AJM; Lopez-Guillermo, A; Luminari, S; Martinelli, G; Rigacci, L; Vitolo, U; Zinzani, PL; Zucca, E | 1 |
| Choi, I; Hata, H; Higuchi, M; Masaki, Y; Nagafuji, K; Sunami, K; Takamatsu, Y; Tamura, K; Uozumi, K | 1 |
| Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J | 1 |
| Beysel, S; Yağci, M; Yeğın, ZA | 1 |
| Chou, T; Hirose, T; Igarashi, N; Imai, Y; Ishiguro, T | 1 |
| Guo, HF; Mao, JJ; Su, HL; Sun, C; Wang, J; Zhou, X | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| Khosroshahi, A; Stone, JH | 1 |
| Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P | 1 |
| Argiris, A; Axelrod, RS; Burtness, B; Deconti, RC; Forastiere, AA; Ghebremichael, M | 1 |
| Assouline, S; Buckstein, R; Chua, NS; Crump, M; Eisenhauer, E; Fernandez, LA; Gascoyne, RD; Klasa, RJ; Kouroukis, CT; Powers, J; Turner, R; Walsh, W | 1 |
| Bladé, J; Harousseau, JL; Lantz, K; Londhe, A; Lowery, C; Orlowski, RZ; Shah, J; Sonneveld, P | 1 |
| Anderson, KC; Armand, P; Bagshaw, M; Banwait, R; Chuma, S; Dollard, A; Ghobrial, IM; Harris, B; Jakubowiak, AJ; Kunsman, J; Laubach, J; Leduc, R; Maiso, P; Munshi, NC; Poon, T; Richardson, PG; Roccaro, A; Rodig, S; Sam, A; Schlossman, R; Vij, R; Warren, D; Weller, E | 1 |
| Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z | 1 |
| Adam, Z; Buchler, T; Gregora, E; Hajek, R; Krejci, M; Krivanova, A; Mayer, J; Minarik, J; Pour, L; Scudla, V; Straub, J; Zahradova, L | 1 |
| Bolaman, Z; Dayanir, V; Dayanir, Y; Kadikoylu, G; Kocaturk, T; Yavasoglu, I | 1 |
| Attal, M; Palumbo, A; Roussel, M | 1 |
| Lonial, S; Mitsiades, CS; Richardson, PG | 1 |
| Cahu, X; Dauriac, C; Houot, R; Lamy, T; Marchand, T; Tas, P | 1 |
| Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A | 1 |
| Coppola, D; Dawson, J; Doyle, A; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Kang, L; Kolla, S; Peer, C; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Shrader, E; Stuart, RK; Sullivan, DM; Talreja, N; Tombes, MB; Wellons, MD; Wright, J | 1 |
| Chott, A; Drach, J; Hoffmann, M; Kaufmann, H; Lamm, W; Raderer, M; Zielinski, C | 1 |
| Arnulf, B; Cavet, J; Deraedt, W; Esseltine, DL; Feng, H; Girgis, S; Grishunina, M; Grosicki, S; Harousseau, JL; Karamanesht, I; Kropff, M; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, T; Shubina, A; van de Velde, H | 1 |
| Mateos, MV | 1 |
| Anderlini, P; Fanale, M; Fayad, L; Horowitz, S; Ji, Y; Kwak, LW; Liboon, MJ; Nunez, C; Popat, U; Pro, B; Samaniego, F; Younes, A | 1 |
| Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P | 1 |
| Albitar, M; Alsina, M; Anderson, KC; Berman, D; Carroll, MP; Chanan-Khan, AA; Krishnan, AY; Lonial, S; Messina, M; Richardson, PG | 1 |
| Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Liu, K; Merlini, G; Palladini, G; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA | 1 |
| Abonour, R; Anderson, KC; Desaiah, D; Ghobrial, IM; Harris, BN; Laubach, JP; Munshi, NC; Myrand, SP; Porter, NM; Richardson, PG; Schlossman, RL; Shi, P; Wooldridge, JE | 1 |
| Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T | 1 |
| Cheson, BD | 1 |
| Ishak, J; Rodrigues, F | 1 |
| Alexanian, R; Delasalle, K; Fu, W; Hou, J; Song, S; Wang, J; Wang, M | 1 |
| Adam, Z; Hájek, R; Jakubcová, R; Klincová, M; Krejcí, M; Mayer, J; Pour, L; Szturz, P; Zahradová, L | 1 |
| Coiffier, B; Crump, M; de Vos, S; Elsayed, YA; Enny, C; Esseltine, DL; Hong, X; Mayer, J; Offner, F; Osmanov, EA; Rule, S; Scheliga, A; Shpilberg, O; Teixeira, A; Theocharous, P; van de Velde, H; Walewski, J; Zhu, E; Zinzani, PL | 1 |
| Bosi, A; Bruno, B; Corradini, P; Einsele, H; Fanin, R; Festuccia, M; Isola, M; Morabito, F; Nozza, A; Nozzoli, C; Patriarca, F; Sperotto, A; Spina, F; Stuhler, G | 1 |
| Antolino, G; Bianchi, MP; De Biase, L; La Verde, G; Monarca, B; Moscetti, A; Porrini, R; Saltarelli, F | 1 |
| Griskevicius, L; Janiulioniene, A; Matuzeviciene, R; Peceliunas, V; Zvirblis, T | 1 |
| Allerton, J; Anderson, KC; Bar, M; Colson, K; Densmore, J; Gardner, L; Ghobrial, IM; Hideshima, T; Irwin, D; Jakubowiak, A; Krishnan, A; Laubach, J; Lonial, S; Martin, T; Munshi, N; Poradosu, E; Raje, N; Richardson, PG; Schlossman, R; Sportelli, P; Wolf, J; Zonder, J | 1 |
| Ailawadhi, S; Bryant, B; Chanan-Khan, A; Gaile, DP; Lee, KP; Mashtare, T; Masood, A; Miecznikowski, J; Mulligan, G; Neuwirth, R; Sher, T; Stein, L; Wang, D; Wilding, GE | 1 |
| Andemariam, B; Coleman, M; Elstrom, RL; Furman, RR; Leonard, JP; Martin, P; Ruan, J; Shore, TB | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Afar, DE; Anderson, KC; Bensinger, W; Benson, DM; Jakubowiak, AJ; Mohrbacher, A; Richardson, PG; Siegel, DS; Singhal, AK; Zimmerman, TM | 1 |
| Bocchia, M; D'Arena, G; D'Auria, F; Defina, M; Gozzetti, A; Musto, P; Papini, G; Statuto, T; Steduto, T | 1 |
| Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Moon, JH; Park, HC; Sohn, SK; Yang, DH | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Pinney, JH; Rannigan, L; Venner, CP; Wechalekar, AD; Whelan, CJ | 1 |
| Ramchandren, R | 1 |
| Andersen, NF; Andréasson, B; Billström, R; Carlson, K; Carlsson, MS; Flogegård, M; Forsberg, K; Gimsing, P; Gulbrandsen, N; Hjertner, Ø; Hjorth, M; Holmberg, E; Karlsson, T; Knudsen, LM; Linder, O; Nahi, H; Othzén, A; Pedersen, PT; Swedin, A | 1 |
| Dispenzieri, A; Kohut, IE; Warsame, R | 1 |
| Chinen, Y; Fuchida, S; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sakamoto, N; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Uchiyama, H; Yamamoto-Sugitani, M | 1 |
| Cheson, BD; Koprivnikar, JL | 1 |
| Arcila, M; Gerecitano, J; Gonzalez, C; Gounder, S; Lin, D; McDonald, A; Mulligan, G; O'Connor, OA; Ogilvie, S; Teruya-Feldstein, J; Zhang, Z; Zheng, J | 1 |
| Olie, RA; Taverna, C; Trojan, A; Voegeli, J; von Rohr, A | 1 |
| Alsina, M; Bahlis, NJ; Belch, A; Gabrail, NY; Jagannath, S; Jakubowiak, AJ; Kaufman, JL; Kukreti, V; Kunkel, LA; Lee, P; Lonial, S; Matous, JV; McDonagh, KT; Orlowski, RZ; Reu, FJ; Rosen, P; Sebag, M; Siegel, DS; Stewart, AK; Vesole, DH; Vij, R; Wang, M; Wear, SM; Wong, AF | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Cakana, A; Casassus, P; Chaleteix, C; de Witte, T; Dib, M; Doyen, C; Fontan, J; Gahrton, G; Garderet, L; Gorin, NC; Gratwohl, A; Hajek, R; Harousseau, JL; Hertenstein, B; Iacobelli, S; Ketterer, N; Koenecke, C; Kolb, B; Lafon, I; Ludwig, H; Masszi, T; Michallet, M; Milone, G; Mohty, M; Moreau, P; Morris, C; Niederwieser, D; Onida, F; Pegourie, B; van Os, M | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Rushworth, SA | 1 |
| Itoh, K; Sasaki, M; Yamaguchi, T | 1 |
| Bostrom, BC; Eckroth, E; Gaynon, PS; Malvar, J; Messinger, YH; Sposto, R; van der Giessen, J | 1 |
| Grant, S; Holkova, B | 1 |
| Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS | 1 |
| Guo, H; Shao, L; Sun, H; Xu, M; Zhou, X; Zhu, J | 1 |
| Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Cilley, J; Evens, AM; Gallot, L; Gordon, LI; Larson, A; Patton, D; Rademaker, A; Roy, R; Spies, S; Variakojis, D; Winter, JN | 1 |
| Lee, KY; Levacque, Z; Rosales, JL | 1 |
| Cakana, A; Deraedt, W; Domnikova, N; Doronin, VA; Esseltine, DL; Facon, T; Feng, H; Girgis, S; Hulin, C; Karamanesht, II; Kyselyova, MY; Leleu, X; Moreau, P; Schmidt, A; Skee, D; van de Velde, H; Venkatakrishnan, K; Vilchevska, KV | 1 |
| Alsina, M; Anderson, KC; Bladé, J; Cavenagh, J; Dalton, W; Danaee, H; Esseltine, DL; Façon, T; Lichter, DI; Lonial, S; Mulligan, G; Niesvizky, R; Pickard, MD; Ricci, D; Richardson, PG; Shi, H; Sintchak, M; Sonneveld, P; Tayber, O; Trepicchio, WL; van de Velde, H | 1 |
| Heelan, K; McKenna, DB | 1 |
| Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A | 1 |
| Camara-Clayette, V; Hermine, O; Ribrag, V | 1 |
| Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA | 1 |
| Cavalli, M; Chiarenza, A; Consoli, U; Conticello, C; Coppolino, F; Di Raimondo, F; Forte, S; Palumbo, GA; Romano, A; Uccello, G; Vetro, C | 1 |
| Bruno, B; Corradini, P; Dodero, A; Fanin, R; Montanari, M; Montefusco, V; Mussetti, A; Offidani, M; Patriarca, F; Scortechini, I; Sperotto, A; Spina, F; Valagussa, P | 1 |
| Berenson, JR; Bessudo, A; Boccia, RV; Gorak, EJ; Gravenor, DS; Kewalramani, T; Mayo, D; Nassir, Y; Noga, SJ; Patel-Donnelly, D; Siegel, RS; Swift, RA; Yellin, O | 1 |
| Ludwig, H; Sonneveld, P | 1 |
| Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T | 1 |
| Benson, DM; Byrd, JC; Devine, SM; Dunavin, NC; Efebera, YA; Elder, P; Greenfield, C; Heerema, N; Hofmeister, CC; Ketcham, J; Merritt, L; Penza, S; Phillips, GS; Rieser, G; Rose, KS; Wei, L | 1 |
| Cavenagh, J; Cook, G; Cook, M; Davies, F; Elliott, P; Gumbleton, T; Jacobson, E; Oakervee, H; Plesner, T; Popat, R | 1 |
| Binkley, P; Blum, KA; Blum, W; Byrd, JC; Garzon, R; Geyer, S; Grever, MR; Jiang, Y; Johnston, JS; Kefauver, C; Klisovic, R; Marcucci, G; Phelps, MA; Walker, AR | 1 |
| Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R | 1 |
| Suzuki, K | 1 |
| Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A | 1 |
| Atwal, S; D'Sa, S; Johnston, R; Khan, I; Moore, S; Narat, S; Percy, L; Rabin, N; Sachchithanantham, S; Schey, S; Streetly, M; Yong, K | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Bernstein, SH; de Vos, S; Esseltine, DL; Fisher, RI; Goy, A; Morrison, VA; Neuwirth, R; Solh, M | 1 |
| Bladé, J; Cibeira, MT; Díaz, T; Fernández de Larrea, C; Martín-Antonio, B; Monzó, M; Navarro, A; Rosiñol, L; Tovar, N; Urbano-Ispizua, A | 1 |
| Anderson, KC; Bailey, C; Chauhan, D; Fanourakis, G; Gu, X; Hideshima, T; Joseph, M; Libermann, TA; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Schlossman, R; Tai, YT | 1 |
| Hattori, Y | 1 |
| Adams, J; Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Esseltine, DL; Hideshima, T; Irwin, D; Jagannath, S; Kauffman, M; Kuter, D; Lee, S; Limentani, SA; Orlowski, RZ; Rajkumar, SV; Richardson, PG; Schenkein, DP; Siegel, D; Singhal, S; Srkalovic, G | 1 |
| Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Guerciolini, R; Kantarjian, H; Koller, C; McConkey, D; Patel, G; Ruiz, SL; Thomas, D; Wright, J | 1 |
| Bostrom, B; Brown, RE; Zhang, PL | 1 |
| Adams, J; Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Esseltine, DL; Irwin, D; Jagannath, S; Kauffman, M; Limentani, SA; Niesvizky, R; Richardson, PG; Schenkein, DP; Siegel, D | 1 |
| Alexanian, R; Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Jagannath, S; Nix, D; Orlowski, RZ; Richardson, PG; Singhal, S; Srkalovic, G | 1 |
| Bruno, B; Fanin, R; Patriarca, F; Prosdocimo, S; Tomadini, V; Vasciaveo, A | 1 |
| Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P | 1 |
| Bruno, B; Gallamini, A; Mattei, D; Mordini, N; Rapezzi, D; Vigna Taglianti, R | 1 |
| Dimopoulos, MA; Rahemtulla, A; Terpos, E | 1 |
| Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, J; Dalton, WS; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Porter, JB; Reece, D; Richardson, PG; San-Miguel, JF; Schenkein, D; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Lokhorst, HM; Sonneveld, P; van Wieringen, W; Vellenga, E; Wu, KL; Zweegman, S | 1 |
| Graeven, U; König, M; Schmiegel, W; Schmielau, J; Teschendorf, C | 1 |
| Anderson, KC; Barlogie, B; Berenson, J; Esseltine, D; Hideshima, T; Irwin, D; Jagannath, S; Rajkumar, SV; Richardson, PG; Schenkein, D; Singhal, S; Xiao, H | 1 |
| Ahmad, K | 1 |
| Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Francis, D; Giusti, S; Giver, CR; Heffner, LT; Jagannath, S; Jaye, DL; Lonial, S; Orlowski, RZ; Richardson, PG; Schenkein, DP; Singhal, S; Torre, C; Waller, EK; Xiao, H | 1 |
| Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R | 1 |
| Caccese, E; Cecchi, M; Messori, A | 1 |
| Kroep, JR; Vandenbroucke, JP | 1 |
| Adam, Z; Gregora, E; Hájek, R; Klener, P; Maisnar, V; Schutzova, M; Scudla, V; Spicka, I; Straub, J; Vytrasová, M | 1 |
| Anderson, K; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Bosi, A; Ciolli, S; Gigli, F; Leoni, F; Rigacci, L | 1 |
| Fayad, L; Pro, B; Younes, A | 1 |
| De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N | 1 |
| Kaufman, JL; Lonial, S; Sinha, R | 1 |
| Bladé, J; Cibeira, MT; Laura, R; Montserrat, E; Salamero, O; Uriburu, C; Yantorno, S | 1 |
| Badros, A; Gahres, N | 1 |
| Balkwill, F; Boral, A; Hoare, S; Joel, SP; Johnson, PW; Lister, TA; Maharaj, L; Millard, L; Radford, JA; Rohatiner, A; Schenkein, D; Strauss, SJ; Trehu, E; Vinnecombe, S | 1 |
| Baccarani, M; Cangini, D; Cavo, M; Ceccolini, M; Perrone, G; Tacchetti, P; Tosi, P; Zamagni, E | 1 |
| Boccadoro, M; Bonifazi, F; Bruno, B; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R | 1 |
| Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Cavallo, F; Falco, P; Falcone, A; Gay, F; Massaia, M; Musto, P; Palumbo, A; Rus, C; Scalzulli, PR | 1 |
| Allegue, F; López-Miragaya, MI; Pérez Castro, S; Romo, M | 1 |
| Berdel, WE; Bisping, G; Kienast, J; Kropff, M; Wenning, D | 1 |
| Colson, K; Jagannath, S; Richardson, P | 1 |
| Jagannath, S | 2 |
| Richardson, P | 1 |
| Bladé, J; Cibeira, MT; Esteve, J; Ramiro, L; Rosiñol, L; Torrebadell, M | 1 |
| Arai, A; Koyama, T; Kurosu, T; Miki, T; Miura, O; Murakami, N; Oshikawa, G; Tohda, S | 1 |
| Arenillas, L; Bladé, J; Cibeira, MT; Mercadal, S; Muntañola, A; Salamero, O | 1 |
| Abonour, R; Juliar, BE; Smith, GG; Suvannasankha, A | 1 |
| Ackermann, J; Drach, J; Kaufmann, H; Küenburg, E; Ludwig, H; Odelga, V; Sagaster, V; Wieser, R; Zielinski, C; Zojer, N | 1 |
| Anagnostopoulos, A; Chantry, A; Croucher, PI; Dimopoulos, MA; Heath, DJ; Katodritou, E; Pouli, A; Rahemtulla, A; Terpos, E; Verrou, E; Vervessou, EC; Zervas, K | 1 |
| Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P | 1 |
| Anderson, KC; Bergsagel, PL; Boral, A; Broyl, A; Bryant, B; Chng, WJ; Esseltine, DL; Fergus, A; Huang, Y; Koenig, E; Mitsiades, C; Mulligan, G; Richardson, P; Roels, S; Schenkein, D; Shaughnessy, JD; Sonneveld, P; Trepicchio, WL; Zhan, F | 1 |
| Boral, AL; Esseltine, DL; Jakob, C; Mehta, J; Richardson, P; Sezer, O; Singhal, S; Stadtmauer, E; Vesole, DH | 1 |
| Dan, K; Gotoh, A; Hotta, T; Ikeda, Y; Ohyashiki, K; Oshimi, K; Usui, N | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Mileshkin, L; Prince, HM; Schenkel, B | 1 |
| Berrebi, A; Duek, A; Feldberg, E; Haran, M | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG | 1 |
| Chen, YB; Fu, WJ; Hou, J; Xi, H; Yang, SL; Yuan, ZG; Zhou, F | 1 |
| Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS | 1 |
| Bergsagel, L; Bryant, B; Chng, WJ; Mulligan, G | 1 |
| Castagna, L; Mazza, R; Nozza, A; Rahal, D; Santoro, A; Sarina, B; Todisco, E | 1 |
| Borchmann, P; Engert, A; Keller, U; Naumann, R; Rummel, M; Sezer, O; Trelle, S | 1 |
| Advani, R; Badros, A; Branagan, AR; Cook, D; Hill, J; Hunter, ZR; Joyce, RM; Kaden, BR; Leleu, X; Mannion, B; Matous, J; Sharon, D; Songer, J; Steiss, R; Treon, SP | 1 |
| Bhandari, M; Jagannath, S | 1 |
| Bocchia, M; Cerase, A; Fabbri, A; Gozzetti, A; Lauria, F; Pirrotta, MT; Tarantino, A | 1 |
| Orlowski, RZ; Voorhees, PM | 1 |
| Adena, M; Hertel, J; Prince, HM; Smith, DK | 1 |
| Berdel, WE; Bisping, G; Dechow, T; Einsele, H; Engelhardt, M; Heinecke, A; Hentrich, M; Kienast, J; Kröger, N; Kropff, M; Lang, N; Liebisch, P; Metzner, B; Salwender, H; Schuck, E; Sezer, O; Volpert, S; Wolf, HH | 1 |
| Calderoni, A; Cornu, P; Freimann, H; Olie, R | 1 |
| Alsina, M; Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, A; Cavenagh, J; Dalton, W; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Jakubowiak, A; Lacy, M; Lonial, S; Miguel, JS; Rajkumar, SV; Reece, D; Richardson, PG; Schenkein, D; Schuster, M; Sonneveld, P; Stadtmauer, E | 1 |
| Alinari, L; Baccarani, M; de Vivo, A; Derenzini, E; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Sabattini, E; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R | 1 |
| Davies, FE; Morgan, GJ; Srikanth, M | 1 |
| Eom, KS; Han, K; Kim, CC; Kim, M; Kim, Y; Lee, JW; Lee, MJ; Lee, S; Lim, J; Min, CK; Min, WS | 1 |
| Gillmore, JD; Hawkins, PN; Lachmann, HJ; Offer, M; Wechalekar, AD | 1 |
| Irvine, AE; McCloskey, SM; McMullin, MF; Walker, B | 1 |
| Aguirre Errasti, C; Alonso Alonso, JJ; Barreiro García, JG; Cánovas Fernández, A | 1 |
| Goy, A; Suh, KS | 1 |
| Encinas García, S; Izarzugaza Perón, Y; Khosravi Shahi, P; Pérez Manga, G; Sabin Domínguez, P | 1 |
| Caplan, SL; Chou, M; Jeng, AY; Jeune, M; Prescott, MF; Sawyer, WK; Von Linden-Reed, J | 1 |
| Chen, D; Li, X; Zou, J | 1 |
| Daffalla, AA; el Tayeb, M; Fenwick, A; Kardaman, MW; See, R | 1 |
| Eule, H | 1 |
48 review(s) available for pyrazines and Recrudescence
| Article | Year |
|---|---|
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles | 2020 |
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Central Nervous System Diseases; Clinical Trials as Topic; Febrile Neutropenia; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Myeloid Differentiation Factor 88; Neoplasm Proteins; NF-kappa B; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Receptors, CXCR4; Recurrence; Salvage Therapy; Signal Transduction; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Protein Kinase Inhibitors; Pyrazines; Recurrence; Research Design | 2018 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Management of double-refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Retreatment; Thalidomide | 2013 |
Second autologous transplant as salvage therapy in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Interferon-alpha; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Reoperation; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
[Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Octreotide; Pancreatitis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Treatment Outcome; Vincristine | 2014 |
Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Hematologic Diseases; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Pneumonia; Proteasome Inhibitors; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2014 |
Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence | 2013 |
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2011 |
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Recurrence | 2011 |
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System Diseases; Oligopeptides; Pyrazines; Recurrence; Thalidomide; Venous Thromboembolism | 2011 |
The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence | 2011 |
[Treatment of adult Ph-negative acute lymphoblastic leukemia].
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Combined Modality Therapy; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Transplantation Conditioning; Young Adult | 2014 |
[Treatment for multiple myeloma: current status and future strategy in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Immunologic Factors; Japan; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide; Time Factors; Transplantation, Autologous | 2008 |
New developments in the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide | 2010 |
Advances in treatment for relapses and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrazines; Recurrence; Thalidomide | 2010 |
How best to use new therapies in multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence | 2010 |
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Topics: Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Boronic Acids; Bortezomib; Humans; Nucleosides; Pyrazines; Recurrence; Rituximab; Signal Transduction; Waldenstrom Macroglobulinemia | 2010 |
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Transcription, Genetic | 2010 |
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Sweden; Thalidomide | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Treatment approaches to IgG4-related systemic disease.
Topics: Antibodies, Monoclonal, Murine-Derived; Autoimmune Diseases; Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunoglobulin G; Immunosuppressive Agents; Pancreatitis; Prognosis; Pyrazines; Recurrence; Rituximab | 2011 |
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Female; Humans; Male; Medical Oncology; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Treatment options for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2011 |
New agents in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment | 2011 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide | 2012 |
Proteasome inhibitors in mantle cell lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Signal Transduction; Survival Analysis | 2012 |
Emerging agents for the treatment of mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Prognosis; Pyrazines; Recurrence; Salvage Therapy; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Watchful Waiting | 2012 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
[Thalidomide treatment in multiple myeloma].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Dexamethasone; Drug Therapy, Combination; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Thalidomide | 2003 |
Current treatment options for myeloma.
Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine | 2005 |
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Therapy; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2005 |
Novel treatment approaches for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drug Design; Heat-Shock Proteins; Histones; Humans; Lenalidomide; Multiple Myeloma; Oncogene Protein v-akt; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Recurrence; Remission Induction; Signal Transduction; Thalidomide | 2006 |
Proteasome inhibition in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Ubiquitin | 2006 |
The emerging role of novel therapies for the treatment of relapsed myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Thalidomide | 2007 |
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2007 |
Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
Topics: Animals; Blood Proteins; Boronic Acids; Bortezomib; Cell Transplantation; Humans; Immunoglobulins; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
The treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
An update on drug combinations for treatment of myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2008 |
The therapeutic potential of the proteasome in leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Gene Expression Regulation, Leukemic; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Biological; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2008 |
Bortezomib in mantle cell lymphoma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2008 |
[Current status of chemotherapy of pulmonary tuberculosis and its further prospectives].
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cycloserine; Drug Resistance, Microbial; Drug Synergism; Drug Tolerance; Hemorrhagic Disorders; Humans; Isoniazid; Kanamycin; Phenylthiourea; Purpura, Thrombocytopenic; Pyrazines; Recurrence; Rifampin; Streptomycin; Tuberculosis, Pulmonary | 1971 |
114 trial(s) available for pyrazines and Recrudescence
| Article | Year |
|---|---|
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
Gilteritinib or Chemotherapy for Relapsed or Refractory
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Mutation; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis | 2019 |
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Neoplasm Proteins; Neutropenia; Pain; Protein Kinase Inhibitors; Pyrazines; Quality of Life; Recurrence; Respiratory Tract Infections; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Topics: Aged; Aniline Compounds; Antineoplastic Agents; Blood Platelets; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Pyrazines; Recurrence; Retreatment | 2017 |
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Topics: Aged; Benzamides; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Recurrence; Survival Analysis; Treatment Outcome | 2018 |
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrazines; Receptors, Antigen, B-Cell; Recurrence; Retreatment; Treatment Outcome | 2019 |
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prospective Studies; Pyrazines; Recurrence; Research Design; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2019 |
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide | 2013 |
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Mice; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Proteasome Inhibitors; Pyrazines; Receptors, IgG; Recurrence; Rituximab; Treatment Outcome | 2011 |
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Survival Analysis | 2014 |
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous | 2014 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence | 2014 |
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Recurrence; Survival Analysis; Thalidomide; Transplantation, Autologous | 2015 |
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2014 |
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo
Topics: Acetylcarnitine; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; NF-kappa B; Nootropic Agents; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Severity of Illness Index; Treatment Outcome | 2014 |
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis | 2014 |
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Drug Monitoring; Female; Flavonoids; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Retreatment; Treatment Outcome | 2014 |
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Double-Blind Method; Female; Humans; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Odds Ratio; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Topics: Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Headache; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Recurrence | 2016 |
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Factor V; Female; Hemostasis; Humans; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Platelet Aggregation; Protein C; Pyrazines; Recurrence; Treatment Outcome | 2008 |
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Evaluation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis | 2008 |
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Recurrence; Virus Activation | 2008 |
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Bone Remodeling; Boronic Acids; Bortezomib; Cytokines; Dexamethasone; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Neovascularization, Physiologic; Pyrazines; Recurrence; Survival Rate; Thalidomide | 2008 |
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epidemiologic Methods; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2008 |
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Treatment Outcome | 2008 |
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Recurrence; Treatment Outcome | 2009 |
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Protocols; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Statistics, Nonparametric; Survival Rate | 2009 |
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Statistics, Nonparametric; Thrombocytopenia | 2009 |
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Ethylenediamines; Humans; Maximum Tolerated Dose; Multiple Myeloma; Organophosphonates; Platelet Count; Pyrazines; Radioisotopes; Recurrence; Samarium | 2009 |
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat | 2009 |
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Pyrazines; Recurrence; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2010 |
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2010 |
Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Female; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Recurrence; Thrombospondins | 2010 |
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Rituximab; Survival Analysis; Waldenstrom Macroglobulinemia | 2010 |
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2011 |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Europe; Female; Humans; Israel; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HSP70 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Neutrophils; Platelet Count; Pyrazines; Recurrence; Treatment Outcome | 2010 |
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Pyrazines; Recurrence; Treatment Failure; Treatment Outcome | 2011 |
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Recurrence; Survival Analysis | 2011 |
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Medical Oncology; Middle Aged; National Health Programs; Pyrazines; Recurrence; Societies, Medical | 2011 |
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Humans; Multiple Myeloma; Myeloma Proteins; Polyethylene Glycols; Pyrazines; Recurrence | 2011 |
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Sirolimus | 2011 |
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2011 |
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide; Treatment Outcome | 2011 |
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Treatment Failure | 2011 |
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2011 |
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Blood Cells; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Europe; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; South America; Treatment Outcome | 2011 |
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Pyrazines; Recurrence; Treatment Outcome; Young Adult | 2011 |
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2011 |
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protease Inhibitors; Pyrazines; Recurrence | 2011 |
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors | 2011 |
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Busulfan; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2011 |
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Infusion Pumps; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Rituximab; Young Adult | 2011 |
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Phosphorylcholine; Pyrazines; Recurrence | 2011 |
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Rituximab; Time Factors; Treatment Outcome | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2012 |
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cross-Over Studies; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Thalidomide | 2012 |
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Proteins; Protein Array Analysis; Pyrazines; Recurrence; Treatment Outcome | 2012 |
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Demography; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2012 |
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Boronic Acids; Bortezomib; Child; Child, Preschool; Dexamethasone; Doxorubicin; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Opportunistic Infections; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Remission Induction; Treatment Outcome; Vincristine; Young Adult | 2012 |
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2012 |
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Pyrazines; Radioimmunotherapy; Recurrence; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2012 |
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dexamethasone; Drug Resistance, Neoplasm; Gene Frequency; Genotype; Humans; Multiple Myeloma; Polymorphism, Single Nucleotide; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines; Recurrence; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2012 |
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence | 2013 |
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Unrelated Donors | 2013 |
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Treatment Outcome | 2013 |
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Dehydration; Drug Resistance, Neoplasm; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Resveratrol; Salvage Therapy; Stilbenes; Treatment Failure; Vomiting | 2013 |
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Electrocardiography; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Male; Middle Aged; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Pyrazines; Recurrence; Torsades de Pointes; Treatment Outcome | 2013 |
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Europe; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemoglobins; Humans; Male; Middle Aged; Multienzyme Complexes; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2003 |
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recurrence; Time Factors | 2004 |
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate | 2004 |
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Count; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate | 2005 |
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Herpes Zoster; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2005 |
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2005 |
Proteasome inhibitor for treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Mice, Inbred BALB C; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Risk Factors; Thrombocytopenia; Treatment Outcome | 2005 |
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Transplantation, Homologous | 2006 |
APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant
Topics: Boronic Acids; Bortezomib; Clinical Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Patient Selection; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy | 2003 |
Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Treatment Outcome | 2006 |
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Stem Cell Transplantation; Treatment Outcome | 2006 |
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cytokines; Doxorubicin; Female; Humans; Lymphoma; Male; Middle Aged; Pyrazines; Recurrence; Tumor Necrosis Factor-alpha | 2006 |
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thalidomide | 2006 |
Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate | 2006 |
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Cohort Studies; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Survival Analysis | 2007 |
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide | 2007 |
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Predictive Value of Tests; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2007 |
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Deletion; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome | 2006 |
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome | 2007 |
Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Multiple Myeloma; Neoplasm Proteins; Ploidies; Pyrazines; Recurrence; Survival Rate | 2007 |
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Treatment Failure | 2007 |
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Immunoglobulin M; Male; Middle Aged; Pyrazines; Recurrence; Time Factors; Treatment Outcome; Waldenstrom Macroglobulinemia | 2007 |
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chi-Square Distribution; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate | 2007 |
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Follow-Up Studies; Humans; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2007 |
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Skin Neoplasms; Treatment Outcome | 2007 |
Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Electrophoresis; Female; Humans; Immunoglobulin Light Chains; Lactate Dehydrogenases; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Recurrence | 2007 |
[A randomized controlled study of ligustrazine in combination with propranolol for prevention of recurrent esophageal varices bleeding].
Topics: Adult; Aged; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Male; Middle Aged; Propranolol; Prospective Studies; Pyrazines; Recurrence | 2000 |
Praziquantel and oltipraz: the treatment of schoolchildren infected with Schistosoma mansoni and/or Schistosoma haematobium in Gezira, Sudan.
Topics: Child; Female; Humans; Male; Parasite Egg Count; Praziquantel; Pyrazines; Random Allocation; Recurrence; Schistosomiasis haematobia; Schistosomiasis mansoni; Schistosomicides; Sex Factors; Sudan; Thiones; Thiophenes | 1988 |
147 other study(ies) available for pyrazines and Recrudescence
| Article | Year |
|---|---|
Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2023 |
Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Topics: Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence; Remission Induction; Reoperation; Tandem Repeat Sequences; Tissue Donors; Treatment Outcome | 2020 |
[Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Topics: Aniline Compounds; Child; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Pyrazines; Recurrence | 2020 |
A comparative prospective study of short-term outcomes of extended view totally extraperitoneal (e-TEP) repair versus laparoscopic intraperitoneal on lay mesh (IPOM) plus repair for ventral hernia.
Topics: Hernia, Inguinal; Hernia, Ventral; Herniorrhaphy; Humans; Laparoscopy; Prospective Studies; Pyrazines; Recurrence; Retrospective Studies; Surgical Mesh; Treatment Outcome | 2021 |
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Topics: Aniline Compounds; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyrazines; Recurrence; Retreatment; Treatment Outcome | 2021 |
Gilteritinib administration in a hemodialysis patient.
Topics: Aged; Aniline Compounds; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Recurrence; Renal Dialysis | 2021 |
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Substitution; Exome Sequencing; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Mutation; Protein Kinase Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Sample Size; Treatment Outcome; Withholding Treatment | 2021 |
Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.
Topics: Amides; China; COVID-19; Humans; Pyrazines; Real-Time Polymerase Chain Reaction; Recurrence; Reverse Transcription; SARS-CoV-2 | 2021 |
Gilteritinib induces differentiation in relapsed and refractory
Topics: Aniline Compounds; Cell Differentiation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines; Recurrence | 2019 |
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Management; Drug Administration Routes; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Recurrence; Risk; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2013 |
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrazines; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
[The combination of chronic myeloid leukemia and multiple myeloma in one patient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Piperazines; Polyneuropathies; Pyrazines; Pyrimidines; Recurrence; Watchful Waiting | 2013 |
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2014 |
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid | 2013 |
Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation.
Topics: Aged; Antibodies; Biopsy; Boronic Acids; Bortezomib; Graft Rejection; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Male; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2013 |
BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Morphogenetic Protein 7; Boronic Acids; Bortezomib; Cell Line, Tumor; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Sequence Data; Neoplasm Staging; Pyrazines; Recurrence; RNA Interference; Treatment Outcome | 2013 |
Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.
Topics: ADAM Proteins; ADAMTS13 Protein; Adolescent; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Recurrence; Remission Induction; Treatment Outcome | 2014 |
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.
Topics: ADAM Proteins; ADAMTS13 Protein; Antineoplastic Agents; Autoantibodies; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Recurrence; Remission Induction | 2014 |
Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 8; Disease-Free Survival; Female; Follow-Up Studies; Gene Amplification; Gene Expression; Genes, myc; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Retrospective Studies | 2014 |
Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Plasmacytoma; Prognosis; Proteasome Inhibitors; Pyrazines; Recurrence; Republic of Korea; Retrospective Studies; Salvage Therapy | 2014 |
Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.
Topics: ADAM Proteins; ADAMTS13 Protein; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Resistance; Female; Glucocorticoids; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Recurrence; Remission Induction; Rituximab; Staphylococcal Infections | 2014 |
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2014 |
Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Imidazoles; Male; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyridazines; Recurrence; Remission Induction | 2014 |
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2014 |
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunoglobulin G; Karyotyping; Male; Middle Aged; Multiple Myeloma; Mutation; Nitrogen Mustard Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; ras Proteins; Recurrence; Signal Transduction; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2014 |
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies | 2014 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure | 2015 |
How I treat relapsed myeloma.
Topics: Adult; Allografts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation | 2015 |
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2015 |
[Multiple myeloma recurring as small intestinal polyposis after autologous hematopoietic stem cell transplantation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Polyposis; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2015 |
Acalabrutinib for relapsed chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines; Recurrence; Retreatment | 2016 |
[Aggravated post-herpetic neuralgia due to bortezomib].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Neuralgia, Postherpetic; Protease Inhibitors; Pyrazines; Recurrence | 2008 |
Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunoglobulins; Male; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Scleromyxedema; Thalidomide | 2008 |
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Nucleus; DNA; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Models, Biological; NF-kappa B; Phosphorylation; Pyrazines; Recurrence; Signal Transduction; Subcellular Fractions | 2008 |
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulins; Male; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; United States | 2008 |
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Time; Treatment Outcome | 2008 |
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Female; Humans; Immunosuppressive Agents; Logistic Models; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pulmonary Embolism; Pyrazines; Recombinant Proteins; Recurrence; Risk; Treatment Outcome; Venous Thrombosis | 2008 |
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies | 2008 |
A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome | 2009 |
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
Topics: Antibodies, Monoclonal; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Glucocorticoids; Humans; Interleukin-6; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence | 2009 |
Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Australia; Boronic Acids; Bortezomib; Cohort Studies; Female; Gastrointestinal Diseases; Humans; International Cooperation; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Recurrence; Treatment Outcome | 2009 |
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
Topics: Aged, 80 and over; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2009 |
Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Time Factors | 2009 |
[Pharmacodynamic characteristics of velcade efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins].
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Neoplasm Staging; Predictive Value of Tests; Prognosis; Pyrazines; Recurrence | 2009 |
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Recurrence; Renal Insufficiency; Risk Factors; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Humans; Insomnia, Fatal Familial; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Transplantation Conditioning | 2009 |
Relapse/Refractory myeloma patient: potential treatment guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Female; Humans; Leukemia, Plasma Cell; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Vincristine | 2010 |
Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Recurrence; Transplantation, Autologous | 2010 |
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2009 |
Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Pyrazines; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2009 |
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Indoles; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence | 2010 |
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Tissue Donors; Transplantation, Homologous | 2011 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide | 2010 |
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease Progression; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat | 2010 |
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Cohort Studies; Female; Humans; Incidence; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neurologic Examination; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; Risk Factors; Severity of Illness Index; Vincristine | 2010 |
Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin kappa-Chains; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Multiple Myeloma; Mycophenolic Acid; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Tacrolimus | 2009 |
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Kaplan-Meier Estimate; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrazines; Recurrence; Retrospective Studies; Time Factors | 2010 |
Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis | 2011 |
Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Prognosis; Pyrazines; Recurrence; Remission Induction; Salvage Therapy | 2010 |
Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2011 |
A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hepatitis B; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2010 |
Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Recurrence; Stroke; Thrombosis; Treatment Outcome | 2010 |
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Costs; Drug Resistance, Neoplasm; Drug Utilization; Female; France; Health Care Costs; Hospitals, University; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Pyrazines; Recurrence; Retrospective Studies; Thalidomide | 2011 |
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Successful treatment of early relapse of ocular myeloma with bortezomib and steroid after autologous stem cell transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Eye Neoplasms; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Plasmacytoma; Prednisolone; Pyrazines; Recurrence; Stem Cell Transplantation | 2010 |
Cutaneous macroglobulinosis treated with bortezomib and rituximab.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Male; Pyrazines; Recurrence; Rituximab; Skin Diseases; Waldenstrom Macroglobulinemia | 2011 |
Subcutaneous bortezomib: a step towards optimised drug use.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Quality of Life; Recurrence | 2011 |
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2012 |
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Sweden; Thalidomide | 2011 |
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2012 |
[Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clodronic Acid; Femur; Humans; Male; Multiple Myeloma; Osteolysis; Pyrazines; Radiography; Recurrence; Remission Induction | 2011 |
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Tissue Donors; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Echocardiography; Female; Humans; Immunoglobulin Light Chains; Pyrazines; Recurrence | 2011 |
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplastic Cells, Circulating; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Microarray Analysis; Multicenter Studies as Topic; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Treatment Failure; Up-Regulation | 2012 |
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasms, Second Primary; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2012 |
A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2012 |
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clonal Evolution; Cohort Studies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2012 |
Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Male; Paraneoplastic Syndromes; POEMS Syndrome; Pyrazines; Recurrence | 2012 |
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Female; Humans; Male; Metaphase; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2012 |
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Proteasome Inhibitors; Pyrazines; Recurrence | 2012 |
Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Switzerland; Time Factors; Treatment Outcome | 2012 |
[Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Dexamethasone; Female; Humans; Intestinal Pseudo-Obstruction; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence | 2012 |
Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Tumor Cells, Cultured | 2012 |
Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Humans; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pyrazines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytokine-Induced Killer Cells; Humans; Immunotherapy, Adoptive; Male; Multiple Myeloma; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome | 2013 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Multiple Myeloma; Pyrazines; Recurrence | 2012 |
Bortezomib-induced cutaneous lupus in a patient with myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2013 |
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug Costs; Health Care Costs; Hospitalization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Multivariate Analysis; Netherlands; Prognosis; Pyrazines; Recurrence; Regression Analysis; Retrospective Studies; Thalidomide; Young Adult | 2013 |
Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2013 |
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Recurrence; Retrospective Studies | 2013 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 1; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Risk Factors | 2013 |
Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Substrate Specificity | 2013 |
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Recurrence; Tumor Cells, Cultured | 2003 |
Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; B-Lymphocytes; Boronic Acids; Bortezomib; Child; Dexamethasone; Humans; Male; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence | 2004 |
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2005 |
Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Tomography, X-Ray Computed; Transplantation, Autologous; Transplantation, Homologous | 2005 |
Bortezomib therapy following first relapse.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2005 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Middle Aged; Multiple Myeloma; Plasma Cells; Plasmacytoma; Pyrazines; Recurrence; Thalidomide | 2005 |
Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2005 |
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Fatal Outcome; Humans; Immunoglobulin D; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Thalidomide | 2005 |
Bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Drug Costs; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate | 2005 |
Bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Data Interpretation, Statistical; Dexamethasone; Follow-Up Studies; Humans; Multiple Myeloma; Pyrazines; Recurrence; Research Design; Survival Analysis | 2005 |
[Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence | 2005 |
Bortezomib-induced Sweet's syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Erectile Dysfunction; Humans; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Prednisolone; Protease Inhibitors; Pyrazines; Recurrence; Sleep Initiation and Maintenance Disorders; Sweet Syndrome; Testicular Diseases | 2005 |
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Soft Tissue Neoplasms; Treatment Outcome | 2006 |
Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2005 |
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
Topics: Adult; Aged; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Survival; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Homologous | 2006 |
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
[Recurrent varicella in a woman with mantle cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chickenpox; Combined Modality Therapy; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Middle Aged; Postoperative Complications; Pyrazines; Recurrence; Transplantation, Autologous | 2006 |
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence | 2006 |
The safety and efficacy of bortezomib in relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate; Treatment Outcome | 2006 |
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Thrombocytopenia; Treatment Outcome | 2006 |
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
[Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Topics: Antineoplastic Agents; Bence Jones Protein; Biomarkers; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome | 2006 |
Bortezomib-induced rhabdomyolysis in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Rhabdomyolysis; Salvage Therapy | 2006 |
Bortezomib dosing in relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate | 2006 |
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Case-Control Studies; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoprotegerin; Peptides; Protease Inhibitors; Pyrazines; RANK Ligand; Recurrence; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2006 |
[Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Hematology; Humans; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Protease Inhibitors; Pyrazines; Recurrence; Risk Factors; Societies, Medical; Stem Cell Transplantation; Surveys and Questionnaires | 2006 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Multiple Myeloma; Pyrazines; Recurrence; Reproducibility of Results; Thalidomide | 2007 |
Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Middle Aged; Multiple Myeloma; Pulmonary Fibrosis; Pyrazines; Recurrence; Respiratory Insufficiency; Steroids; Treatment Failure | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
[Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2006 |
Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Chronic Disease; gamma-Glutamyltransferase; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction | 2007 |
Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma.
Topics: Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Treatment Outcome | 2007 |
Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cavernous Sinus; Fatal Outcome; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Sensitivity and Specificity; Treatment Outcome | 2007 |
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Switzerland; Thrombocytopenia; Treatment Outcome | 2007 |
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
Topics: Amyloidosis; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Male; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2008 |
[Bortezomib in relapsed or refractory multiple myeloma: results in a cohort of 39 patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence | 2008 |
[Efficiency of bortezomib and dexamethasone in relapsed multiple myeloma treatment: retrospective study in consecutive cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Survival Rate | 2008 |
Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Arteriosclerosis; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Movement; Collagenases; Elastin; Hydroxamic Acids; Male; Matrix Metalloproteinase 12; Matrix Metalloproteinase 13; Matrix Metalloproteinase 3; Metalloendopeptidases; Mice; Mice, Knockout; Protease Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, LDL; Recurrence; Sulfonamides; Transcription, Genetic | 1999 |